5_guidelines tb.doc
TRANSCRIPT
-
8/8/2019 5_Guidelines TB.doc
1/161
guidelinesFourth edition
TreaTmenT of Tuberculosis
-
8/8/2019 5_Guidelines TB.doc
2/161
-
8/8/2019 5_Guidelines TB.doc
3/161
Treatment of
tuberculosis
GuidelinesFourth edition
WHO Library Cataloguing-in-Publication Data:
Treatment of tuberculosis: guidelines – 4th ed
WHO!HT"!T#!$%%&4$%
'(ntitubercular agents – administration and dosage $Tuberculosis) Pulmonary
– drug thera*y +,ational health *rograms 4Patient com*liance
-
8/8/2019 5_Guidelines TB.doc
4/161
.uidelines /World Health Organi0ation 1to* T# De*t
/1#, &23 &$ 4 '423+ + ,L" classification: W5 +6%7
© World Health Organization 2010
(ll rights reser8ed Publications of the World Health Organi0ation can be obtained from WHO Press)
World Health Organi0ation) $% (8enue (**ia) '$'' .ene8a $2) 19it0erland tel: 4' $$ 2&' 432; e-
mail: booe?uests for *ermission to re*roduce or translate WHO *ublications –
9hether for sale or for noncommercial distribution – should be addressed to WHO Press) at the abo8e
address fa@: 4' $$ 2&' 43%6; e-mail: *ermissions=9hoint7
The designations em*loyed and the *resentation of the material in this *ublication do not im*ly thee@*ression of any o*inion 9hatsoe8er on the *art of the World Health Organi0ation concerning the legal
status of any country) territory) city or area or of its authorities) or concerning the delimitation of its
frontiers or boundaries Dotted lines on ma*s re*resent a**ro@imate border lines for 9hich there may not
yet be full agreement
The mention of s*ecific com*anies or of certain manufacturersA *roducts does not im*ly that they are
endorsed or recommended by the World Health Organi0ation in *reference to others of a similar nature
that are not mentioned Brrors and omissions e@ce*ted) the names of *ro*rietary *roducts are
distinguished by initial ca*ital letters
(ll reasonable *recautions ha8e been ta
-
8/8/2019 5_Guidelines TB.doc
5/161
Acknowledgements viii
Foreword ix
Executive summary 1
1. Introduction 15
1.1 Chapter objectives 1
1.! "urpose of the guidelines 1
1.# Target audience 1
1.$ scope 1
1. %h& a new edition' 1
1.( )ethodolog& 1*
1.+ international standards for Tuberculosis Care !1
1.* expir& date !1 2. Case definitions 23
!.1 Chapter objectives !#
!.! "urposes of defining a T, case !#
!.# Case definitions !#
!.$ Anatomical site of T, disease !$
!. ,acteriological results !
!.( -istor& of previous treatment patient registration group !(
!.+ -i/ status !*
3. Standard treatment regimens 29
#.1 Chapter objectives !0
#.! Aims of treatment !0
#.# essential antiT, drugs !0
#.$ standard regimens for defined patient groups #1
#. new patients #!
#.( "reviousl& treated patients and multidrug resistance #(
#.+ standard regimens for previousl& treated patients #*
#.* 2verall considerations in selecting a countr&3s standard
regimens $!
rEamEn of u!ErCu"oSIS: #uIdE"InES
$. monitoring during treatment 53
$.1 Chapter objectives #
$.! )onitoring the patient #
v
-
8/8/2019 5_Guidelines TB.doc
6/161
$.# Assessing treatment response in new and previousl& treated
pulmonar&
T, patients4 and acting on the results #
$.$ extrapulmonar& T, +
$. 5ecording standardi6ed treatment outcomes +$.( Cohort anal&sis of treatment outcomes +
$.+ )anagement of treatment interruption 0
$.* "revention of adverse effects of drugs 0
$.0 )onitoring and recording adverse effects (7
$.17 s&mptombased approach to managing sideeffects of antiT,
drugs (7
5. Co%management of &I' and active ! disease (5
.1 Chapter objectives (
.! -i/ testing and counselling for all patients known or suspected
to have T, (
.# -i/ prevention in T, patients (+
.$ T, treatment in people living with -i/ (+
. Cotrimoxa6ole preventive therap& (0
.( Antiretroviral therap& (0
.+ drug susceptibilit& testing +1
.* "atient monitoring during T, treatment +1
.0 Considerations when T, is diagnosed in people living with -i/
who are
alread& receiving antiretroviral therap& +!
.17 -i/related prevention4 treatment4 care and support +!
(. Su)ervision and )atient su))ort *5
(.1 Chapter objectives +(.! 5oles of the patient4 T, programme staff4 the communit& and
other providers +
(.# supervised treatment ++
(.$ using a patientcentred approach to care and treatment deliver&
+*
(. "revention of treatment interruption *7
*. reatment of drug%resistant tu!ercu"osis +3
+.1 Chapter objectives *#
+.! Green light Committee initiative *#
+.# Groups of drugs to treat )d5T, *$
iv
-
8/8/2019 5_Guidelines TB.doc
7/161
+.$ General principles in designing an )d5T, treatment regimen
*(
ConEnS
+. "rogrammatic strategies for treatment of )d5T, *(
+.( selection of the countr&3s standard )d5T, treatment regimen
*0
+.+ selection of individuali6ed )d5T, regimens *0
+.* )onitoring the )d5T, patient 01
+.0 duration of treatment for )d5T, 01
+.17 Treating T, with resistance patterns other than )d5 0!
+.11 5ecording and reporting drugresistant T, cases4 evaluation of
outcomes 0!
+. reatment of extra)u"monary ! and of ! in s)ecia" situations
95
*.1 Chapter objectives 0
*.! Treatment of extrapulmonar& T, 0
*.# important drug interactions 0(
*.$ Treatment regimens in special situations 0+
annexes 1,1
1. essential firstline antituberculosis drugs 17#
!. summar& of evidence and considerations underl&ing the
recommendations 11
#. T, treatment outcomes 1#1
$. implementation and evaluation of the fourth edition 1##
. suggestions for future research 1$1
(. )embers of the Guidelines Group 1$
v
-
8/8/2019 5_Guidelines TB.doc
8/161
-
8/8/2019 5_Guidelines TB.doc
9/161
Abbreviations
(5# acid-fast bacilli
(/D1 ac?uired immunodeficiency syndrome
(>T antiretro8iral thera*y
DOT directly obser8ed treatment
DOT1 the internationally agreed strategy for T# control
D>1 drug resistance sur8eillance
D1T drug susce*tibility testing
B ethambutol
BPT# e@tra*ulmonary tuberculosis
B( e@ternal ?uality assurance
5DC fi@ed-dose combination
.LC .reen Light Committee
H isonia0id
H/E human immunodeficiency 8irus
/1TC /nternational 1tandards for Tuberculosis Care
"D> multidrug resistance
"D>-T# multidrug-resistant tuberculosis
,,>T/ non-nucleoside re8erse transcri*tase inhibitor
,>T/ nucleoside re8erse transcri*tase inhibitor
,TP national tuberculosis control *rogramme
PT# *ulmonary tuberculosis> rifam*icin
1 stre*tomycin
T# tuberculosis
T#!H/E H/E-related T#
FD>-T# e@tensi8ely drug-resistant tuberculosis
G *yra0inamide
: :
i
x
-
8/8/2019 5_Guidelines TB.doc
10/161
Acknowledgements
The 1to* T# De*artment of the World Health Organi0ation gratefully acGB!4H>7 9ill reduce the number of rela*ses and failures This 9ill
alle8iate *atient suffering resulting from a second e*isode of tuberculosis T#7 and
conser8e *atient and *rogramme resources
1econd) this fourth edition confirms *rior WHO recommendations for drug
susce*tibility testing D1T7 at the start of thera*y for all *re8iously treated *atients
5inding and treating multidrug-resistant T# "D>-T#7 in *re8iously treated
: :
v
ii
-
8/8/2019 5_Guidelines TB.doc
11/161
*atients 9ill hel* to im*ro8e the 8ery *oor outcomes in these *atients ,e9
recommendations for the *rom*t detection and a**ro*riate treatment of "D>-T#7
cases 9ill also im*ro8e access to life-sa8ing care The retreatment regimen 9ith
first-line drugs formerly called MCategory $N regimen7 is ineffecti8e in "D>-T#; it
is therefore critical to detect "D>-T# *rom*tly so that an effecti8e regimen can be
started Third) detecting "D>-T# 9ill re?uire e@*ansion of D1T ca*acity 9ithin the
conte@t of country-s*ecific) com*rehensi8e *lans for laboratory strengthening This
fourth edition *ro8ides guidance for treatment a**roaches in the light of ad8ances in
laboratory technology and the countryAs *rogress in building laboratory ca*acity /n
countries that use the ne9 ra*id molecular-based tests) D1T results for rifam*icin!
isonia0id 9ill be a8ailable 9ithin ' $ days and can be used in deciding 9hich ‒
regimen should be started for the indi8idual *atient >a*id tests eliminate the need to
treat Min the dar17 data or sur8eys 9ill be re?uired to identify subgrou*s of T#
*atients 9ith the highest *re8alence of "D>-T#) such as those 9hose *rior
treatment has failed /m*lementation of these recommendations 9ill re?uire e8erycountry to include an "D>-T# regimen in its standards for treatment in
collaboration 9ith the .reen Light Committee /nitiati8e
: :
i
x
-
8/8/2019 5_Guidelines TB.doc
12/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
5ourth) diagnosing "D>-T# cases among *re8iously treated *atients and *ro8iding
effecti8e treatment 9ill greatly hel* in halting the spread of "D>-T# This edition
also addresses the *re8ention of acquired "D>-T#) es*ecially among ne9 T#
*atients 9ho already ha8e isonia0id-resistant Mycobacterium tuberculosis 9hen they
start treat ment The meta-analyses that form the e8idence base for this re8ision
re8ealed that ne9 *atients 9ith isonia0id-resistant T# ha8e a greatly increased ris
-
8/8/2019 5_Guidelines TB.doc
13/161
T#!H/E and multidrug-resistant T# "D>-T#7 The 1to* T# 1trategy and the
.lobal Plan to im*lement the ne9 strategy maecommendations 9ere rated as MstrongN or MconditionalN
The e8idence and considerations underlying each recommendation are summari0ed
in (nne@ $
( strong recommendation is one for 9hich desirable effects of adherence to the
recommendation clearly out9eigh the undesirable effects The strong
recommendations in this edition use the 9ords MshouldN or Mshould notN ,o
alternati8es are listed
( conditional recommendation is one for 9hich the desirable effects of adherence to
the recommendation *robably out9eigh the undesirable effects but the trade-offs are
uncertain
>easons for uncertainty can include:
lac< of high-?uality e8idence to su**ort the recommendation;
limited benefits of im*lementing the recommendation;
costs not ustified by the benefits; im*recise
estimates of benefit
( weak recommendation is one for 9hich there is insufficient e8idence and it is
based on field a**lication and e@*ert o*inion >ecommendations for 9hich the
?uality of e8idence 9as not assessed in line 9ith the .>(DB methodology are not
rated
Conditional and 9ea< recommendations use the 9ords MmayN 5or se8eral of the
conditional recommendations) alternati8es are listed
The recommendations that address each of the se8en ?uestions are listed belo9) and
also a**ear in bold te@t in Cha*ter + 1tandard treatment regimens7) Cha*ter 4
"onitoring during treatment7 and Cha*ter Co-management of H/E and acti8e
T#7 (reas outside the sco*e of the se8en ?uestions) as 9ell as the remaining
cha*ters) ha8e been u*dated 9ith current WHO T# *olicies and recent references
but 9ere not the subect of systematic literature re8ie9s or of ne9 recommendations by the .uidelines .rou*
x
i
-
8/8/2019 5_Guidelines TB.doc
14/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
-uestion 1. duration of rifam)icin in ne )atients
1hould ne9 *ulmonary T# *atients be treated 9ith the 6-month rifam*icin regimen
$H>GB!4H>7 or the $-month rifam*icin regimen $H>GB!6HB7
L Recommendation 1.1
New patients with pulmonary T should recei!e a regimen containing "months o# ri#ampicin$ 2HR%&'(HR
1trong!High grade of e8idence7
Remark a: >ecommendation '' also a**lies to e@tra*ulmonary T#) e@ce*t T# of
the central ner8ous system) bone or oint for 9hich some e@*ert grou*s suggest
longer thera*y see Cha*ter 37
Remark b: WHO recommends that national T# control *rogrammes ensure that
su*er8ision and su**ort are *ro8ided for all T# *atients in order to achie8e
com*letion of the full course of thera*y
Remark c: WHO recommends drug resistance sur8eys or sur8eillance7 for
monitoring the im*act of the treatment *rogramme as 9ell as for designing
standard regimens
L Recommendation 1.2
The 2HR%&'"H& treatment regimen should )e phased out
1trong!High grade of e8idence7
-uestion 2. dosing fre/uency in ne )atients
When a country selects $H>GB!4H>) should *atients be treated 9ith a daily or three
times 9eeecommendation $':
x
i
-
8/8/2019 5_Guidelines TB.doc
15/161
ExECuI'E Summary
L Recommendation 2.1,
New patients with pulmonary T may recei!e a daily intensi!e phase
#ollowed )y a three times wee-ly continuation phase 2HR%&'(/HR *
pro!ided that each dose is directly o)ser!ed
Conditional!High and moderate grade of e8idence7
L Recommendation 2.1
Three times wee-ly dosing throughout therapy 2/HR%& '(/HR may )e
used as another alternati!e to Recommendation 2.1* pro!ided that e!ery
dose is directly o)ser!ed and the patient is NOT li!ing with H34 or li!ing
in an H345pre!alent setting
Conditional!High and moderate grade of e8idence7
Remark a: Treatment regimens for T# *atients li8ing 9ith H/E or li8ing in
H/E-*re8alent settings are discussed in >ecommendation 4 and Cha*ter
Remark b: /n terms of dosing fre?uency for H/E-negati8e *atients) the
systematic re8ie9 found little e8idence of differences in failure or rela*se rates
9ith daily or three times 9ee
-
8/8/2019 5_Guidelines TB.doc
16/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
L Recommendation
3n populations with -nown or suspected high le!els o# isoniazid resistance*
new T patients may recei!e HR& as therapy in the continuation phase as an
accepta)le alternati!e to HR
Wea
Remark a: While there is a *ressing need to *re8ent multidrug resistance "D>7)
the most effecti8e regimen for the treatment of isonia0id-resistant T# is not
-
8/8/2019 5_Guidelines TB.doc
17/161
ExECuI'E Summary
1trong!High grade of e8idence7
L Recommendation (.
3# a daily continuation phase is not possi)le #or these patients* three times
wee-ly dosing during the continuation phase is an accepta)le alternati!e
Conditional!High and moderate grade of e8idence7
L Recommendation (.(
/t is recommended that T# *atients 9ho are li8ing 9ith H/E should recei8e at
least the same duration of T# treatment as H/E-negati8e T# *atients
1trong!High grade of e8idence7
Remark a: 1ome e@*erts recommend *rolonging T# treatment in *ersons li8ing
9ith H/E see Cha*ter 7
Remark b: Pre8iously treated T# *atients 9ho are li8ing 9ith H/E should recei8e
the same retreatment regimens as H/E-negati8e T# *atients
>ecommendations '–4 as they relate to ne9 *atients7 are summari0ed in Table (
belo9) and sho9n in Tables +$ and ++ in Cha*ter +
Table A 8TAndArd regimen And do8ing fre9uenc& for new T, pATienT8
Intensive )hase Continuation
)hase
Comments
! months of -r:ea $ months of -r
! months of -r:e $ months of -re Applies onl& in countries with high levels
of isonia6id resistance in new T,
patients4 and where isonia6id drug
susceptibilit& testing in new patients is
not done ;or results are unavailable<
before the continuation phase beginsa w-o no longer recommends omission of ethambutol during the intensive phase of treatment
for patients with noncavitar&4 smearnegative pulmonar& T, or extrapulmonar& disease whoare known to be -i/negative.
dosing fre/uency
Comments
Intensive )hase Continuation )hase
dail& dail& optimal
dail& # times per week Acceptable alternative for an& new T,
patient receiving directl& observed
therap&
# times per week # times per week Acceptable alternative provided that thepatient is receiving directl& observed
therap& and is noT living with -i/ or
living in an -i/prevalent setting ;see
chapter <
9
-
8/8/2019 5_Guidelines TB.doc
18/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
Note dail& ;rather than three times weekl&< intensivephase dosing ma& help to prevent
ac9uired drug resistance in T, patients starting treatment with isonia6id resistance ;see Annex
!
-
8/8/2019 5_Guidelines TB.doc
19/161
ExECuI'E Summary
*ositi8e at the start of treatment Patients 9hose s*utum smears are *ositi8e at
month or 6 or 9ho are found to harbour "D>-T# strains at any time7 9ill be
re-registered as ha8ing failed treatment and be treated according to
>ecommendation 2 belo9
L Recommendation 8.(
3n pre!iously treated patients* i# the specimen o)tained at the end o# the
intensi!e phase /month is smear5positi!e* sputum culture and drug
suscepti)ility testing /9:T should )e per#ormed
1trong!High grade of e8idence7
-uestion (. reatment extension in ne )u"monary ! )atients
/n ne9 *ulmonary T# *atients) ho9 effecti8e is e@tension of treatment for *re8enting failure or rela*se
L Recommendation "
3n patients treated with the regimen containing ri#ampicin throughout
treatment* i# a positi!e sputum smear is #ound at completion o# the intensi!e
phase* the e6tension o# the intensi!e phase is not recommended
1trong!High grade of e8idence7
Remark: WHO recommends that a *ositi8e s*utum smear at com*letion of the
intensi8e *hase should trigger a careful re8ie9 of the ?uality of *atient su**ort
and su*er8ision) 9ith *rom*t inter8ention if needed see Cha*ter 47 /t should
also trigger additional s*utum monitoring) as *er >ecommendations $) + and
4
-uestion *. revious"y treated )atients
Which if any7 grou*s of *atients should recei8e a retreatment regimen 9ith first-
line drugs
Table + in Cha*ter + sho9s >ecommendations 2'–24
L Recommendation ;.1
:pecimens #or culture and drug suscepti)ility testing /9:T should )e
o)tained #rom all pre!iously treated T patients at or )e#ore the start o#
treatment. 9:T should )e per#ormed #or at least isoniazid and ri#ampicin
Remark a: D1T may be carried out by ra*id molecular-based methods or by
con8entional methods 1*utum should be obtained) as 9ell as a**ro*riate
s*ecimens for e@tra*ulmonary T#) de*ending on the site of disease
Remark b: Obtaining s*ecimens for culture and D1T should not delay the start of
treatment Bm*irical thera*y should be started *rom*tly) es*ecially if the *atient
is seriously ill or the disease is *rogressing ra*idly
9
-
8/8/2019 5_Guidelines TB.doc
20/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
L Recommendation ;.2
3n settings where rapid molecular5)ased 9:T is a!aila)le* the results should
guide the choice o# regimen
L Recommendation ;.3n settings where rapid molecular5)ased 9:T results are not routinely a!aila)le
to guide the management o# indi!idual patients* empirical 1 treatment should )e
started as #ollows$
L Recommendation ;..1
T patients whose treatment has failed 2 or other patient groups with high
li-elihood o# multidrug5resistant T /-T# are
those rela*sing or defaulting after their second or subse?uent course of
treatment 1ee also section +3$
L Recommendation ;..2
T patients returning a#ter de#aulting or relapsing #rom their #irst
treatment course may recei!e the retreatment regimen containing #irst5
line drugs 2HR%&:'1HR%&'8HR& i# country5speci#ic data show low ormedium le!els o#
-
8/8/2019 5_Guidelines TB.doc
21/161
ExECuI'E Summary
Table # belo9 lists
-
8/8/2019 5_Guidelines TB.doc
22/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
S ( trial of broad-s*ectrum antibiotics is no longer recommended to be used
as a diagnostic aid for smear-negati8e *ulmonary T# in *ersons li8ing 9ith H/E
S 5or H/E-negati8e *atients) the fourth edition s*ecifies that) if broad-
s*ectrum antibiotics are used in the diagnosis of smear-negati8e *ulmonary T#)anti-T# drugs and fluoro?uinolones should be a8oided
S Pulmonary T# cases 9ithout smear results are no longer classified as
smear- negati8e /nstead) they are labelled Msmear not doneN on the T# register
and in the annual WHO sur8ey of countries
S Consistent 9ith 1tandard + of the /nternational 1tandards for T# Care)
culture and histo*athological e@amination are recommended for s*ecimens from
sus*ected e@tra*ulmonary sites of T# B@amination of s*utum and a chest
radiogra*h are also suggested) in case *atients ha8e concomitant *ulmonaryin8ol8ement
S The *atient registration grou* MOtherN no longer includes MchronicN
/nstead) *atients 9hose s*utum is smear-*ositi8e at the end of or returning from7
a second or subse?uent course of treatment are classified by the outcome of their
most recent retreatment course: rela*sed) defaulted or failed
Cha)ter 3. standard treatment regImens
S (dditional dosage information is *ro8ided for isonia0id ma@imum daily
dose for three times *er 9ee
-
8/8/2019 5_Guidelines TB.doc
23/161
ExECuI'E Summary
le8els of isonia0id resistance This conditional recommendation a**lies 9here
isonia0id susce*tibility testing in ne9 *atients is not done or results are not
a8ailable7 before the continuation *hase begins
S D1T before or at the start of thera*y is strongly recommended for all *re8iously treated *atients
S Pre8iously treated *atients are defined by their li regimen is
recommended for *atients 9ith high li regimen is no9 recommended as one of each countryAs standard
regimens) for use in confirmed "D>-T# cases as 9ell as in *atients 9ith a high
li treatment is no longer an acce*table rationale for
*ro8iding a retreatment regimen of first-line drugs formerly called the MCategory
$ regimenN7 to *atients 9ith a high li-T# that are high enough to 9arrant an "D>
regimen 9hile a9aiting results of D1T
S WHO does not intend to establish thresholds for lo9) moderate) or high
li in s*ecific *atient grou*s) as 9ell asother factors such as "D> treatment resources a8ailable during scale-u*) and
fre?uency of concomitant conditions such as H/E7 that increase the short-term
ris< of dying from "D>-T#
9
-
8/8/2019 5_Guidelines TB.doc
24/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
S Country drug resistance sur8eys) WHO estimates of "D> le8els) and other
data sources are recommended to inform decisions on each countryAs standard
treatment regimens for defined *atient grou*s
S /ntermittent dosing is no longer an o*tion for *re8iously treated *atientsrecei8ing the 3-month retreatment regimen 9ith first-line drugs
Cha)ter $. monItorIng durIng treatment
S The *erformance of s*utum smear microsco*y at the com*letion of the
intensi8e *hase of treatment is a conditional) rather than a strong)
recommendation) gi8en the e8idence that a *ositi8e smear at this stage has a 8ery
*oor ability to *redict rela*se or *retreatment isonia0id resistance (nne@ $7
Ho9e8er) its utility in detecting *roblems 9ith *atient su*er8ision and for
monitoring *rogramme *erformance is reaffirmed
S /n addition) this edition recommends that a *ositi8e s*utum smear at the
end of the intensi8e *hase in ne9 *atients should trigger s*utum smear
microsco*y at the end of the third month /f the latter is *ositi8e) culture and D1T
should be *erformed
S This edition no longer recommends e@tension of the intensi8e *hase for
*atients 9ho ha8e a *ositi8e s*utum smear at the end of the second month of
treatment
S /n *re8iously treated *atients) if the s*ecimen obtained at the end of the
intensi8e *hase month +7 is smear-*ositi8e) this edition recommends that s*utum
culture and D1T be *erformed then) rather than 9aiting until month 9hich 9as
recommended in the third edition7
S The outcome of cure no9 encom*asses culture results
S Patients found to harbour an "D>-T# strain at any *oint during treatment
are no9 classified as Mtreatment failureN They are re-registered and begin an
"D> regimen
S 5or "D>-T# *atients) this edition recommends the use of the "D>-T#
register and cohort analysis
S The sym*tom-based a**roach to side-effects of anti-T# drugs has been
re8ised
Cha)ter 5. Co%management of hI' and aCtI'e t dIsease
S Pro8ider-initiated H/E testing for all *atients 9ith
-
8/8/2019 5_Guidelines TB.doc
25/161
ExECuI'E Summary
S Daily dosing is strongly recommended during the intensi8e *hase for T#
*atients 9ith
-
8/8/2019 5_Guidelines TB.doc
26/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
S 1tre*tomycin: dosage adustments for the elderly and adults 9eighing less
than %
-
8/8/2019 5_Guidelines TB.doc
27/161
introduction
1.1 Cha)ter o!ectives
This cha*ter defines the *ur*ose) target audience) sco*e and de8elo*ment of this
fourth edition of the guidelines /t also e@*lains 9hy a ne9 edition 9as needed and
*roects a date for the ne@t re8ision
1.2 ur)ose of the guide"ines
The *rinci*al *ur*ose of these guidelines is to hel* national T# control *rogrammes,TPs7 in setting T# treatment *olicy to o*timi0e *atient cure: curing *atients 9ill
*re8ent death) rela*se) ac?uired drug resistance) and the s*read of T# in the
community Their further *ur*ose is to guide clinicians 9or-T#7 The 1to* T# 1trategy and the .lobal Plan
1
1
5
-
8/8/2019 5_Guidelines TB.doc
28/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
27 to im*lement the ne9 strategy made it necessary to re8ise the e@isting guidelines
7 and de8elo* this fourth edition
Historically) the greatest em*hasis of T# control acti8ities has been on the most
infectious *atients – those 9ho ha8e s*utum smear-*ositi8e *ulmonary tuberculosis
7 This changed 9ith the 1to* T# 1trategyAs em*hasis on uni8ersal access for all *ersons 9ith T# to high-?uality) *atient-centred treatment 17 Ho9e8er) highly
infectious) smear-*ositi8e *atients remain the *rimary focus for other as*ects of T#
control) including contact tracing and infection control The PatientsA Charter for T#
Care s*ecifies that all T# *atients ha8e Mthe right to free and e?uitable access to T#
care) from diagnosis through treatment com*letionN !7
This fourth edition of the guidelines has therefore abandoned Categories /–/E) 9hich
9ere used to *rioriti0e *atients for treatment' (ccording to this *rior categori0ation)
smear-negati8e T# *atients 9ere assigned third *riority and "D>-T# *atients
fourth *riority 5or treatment decisions it no longer maegistration
grou*s for *re8iously treated *atients are based on the outcome of their *rior
treatment course: failure) rela*se) and default
The fourth edition integrates detection and treatment of both H/E infection and
"D>-T#) and thus should contribute to9ards achie8ement of the 1to* T#
1trategyAs uni8ersal access to high-?uality "D>-T# and H/E care
With regard to H/E detection) this edition incor*orates recent WHOrecommendations for *ro8ider-initiated H/E testing of all *ersons 9ith diagnosed or
sus*ected T#) in all ty*es of H/E e*idemics lo9-le8el) concentrated or generali0ed7
%7 5or treatment of T# in *ersons li8ing 9ith H/E) ne9 recommendations on the
duration of thera*y and the role of intermittent regimens ha8e emerged from
systematic re8ie9s see Cha*ter 7 The ne9 edition also includes recent WHO
recommendations for D1T at the start of T# thera*y in all *eo*le li8ing 9ith H/E
&7) as 9ell as recommendations on the timing and ty*e of antiretro8iral thera*y
(>T7 regimens 1'7
' (lso) the original one-to-one corres*ondence bet9een *atient grou* and treatment regimens 9as lost
as Categories /–/E 9ere redefined o8er the years The same treatment regimen came to berecommended for *atients in Categories / and ///; after $%%4) different treatment regimens 9ere
recommended for *atients in Category // de*ending on factors such as *rogramme *erformance and
drug resistance
2
2
-
8/8/2019 5_Guidelines TB.doc
29/161
1. InroduCIon
,e9 de8elo*ments in "D>-T# also contributed to the need for this re8ision
#uilding on the *rinci*le of uni8ersal access to "D>-T# diagnosis and care) T(e
MDR)T* and +DR)T* response plan 2''$,2''% 117 calls for the diagnosis and
treatment of "D>-T# in all countries by $%' B8en countries 9ith lo9 o8erall
le8els of multidrug resistance "D>7 are faced 9ith T# *atients 9ho ha8e been
*re8iously treated – a grou* that is fi8e times more li-T# diagnosis) this fourth edition
reaffirms e@isting WHO recommendations 27 that all *re8iously treated *atients
should ha8e access to culture and D1T at the beginning of treatment) in order to
identify "D>-T# as early as *ossible' /t also incor*orates the WHO
recommendation that treatment failure be confirmed by culture and D1T &7 /n
order to detect "D> sooner than the end of the fifth month of treatment) this edition
includes the e@isting WHO recommendation &7 for culture and D1T if *atients stillha8e smear-*ositi8e s*utum at the end of the third month of treatment
Cha*ters $– of this ne9 edition discuss the critical role of the identification of
Mycobacterium tuberculosis and of D1T This is in contrast to the *re8ious edition)
9hich relied almost e@clusi8ely on smear microsco*y for case definition) assignment
of standard regimens) and monitoring of treatment res*onse Line *robe assays can
identify "D>-T# 9ithin hours and li?uid media can do so 9ithin 9ee
regimen in its standard regimens This is essential 9hile a9aiting D1T results for
*atients 9ith a high li-T# treatment is no
longer an acce*table rationale for *ro8iding the 3-month retreatment regimen 9ith
first-line drugs formerly called the MCategory // regimenN7 to *atients 9ith a highli-T# and may result
in am*lification of drug resistance ") 17
Ise of ra*id D1T methods 9ill e8entually render the 3-month retreatment regimen
of first-line drugs obsolete /n the meantime) the regimen is retained in this fourth
edition in only t9o circumstances /n countries 9ith access to routine D1T using
con8entional methods) the 3-month retreatment regimen 9ith first-line drugs is
recommended 9hile a9aiting D1T results from *atients 9ho ha8e rela*sed or are
returning after default if country-s*ecific data sho9 they ha8e a medium li
-
8/8/2019 5_Guidelines TB.doc
30/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
of "D>-T#) or if such data are una8ailable7 /n countries that do not yet ha8e D1T
routinely a8ailable at the start of treatment for all *re8iously treated *atients see
section +2+7) the 3-month retreatment regimen 9ith first-line drugs 9ill be used for
the duration of treatment on an interim basis until laboratory ca*acity is a8ailable
/n *rinci*le) "D> treatment should be introduced only in 9ell-*erforming DOT1 *rogrammes #efore focusing on curing "D>-T# cases) it is critical to Mturn off the
ta*N) ie to strengthen *oor *rogrammes so that they sto* gi8ing rise to "D>-T#
5ollo9ing this *rinci*le) the $%%4 re8ision of the treatment cha*ter ' listed ade?uate
*erformance of a countryAs o8erall T# *rogramme as a re?uirement for the use of
"D> regimens in *atients 9ith a high li *ilot *roect that) once established)
can *ro8ide a model and an im*etus for the e@*ansion of basic DOT1 into more
areas /n most countries) ho9e8er) conditions for initiating an "D> com*onent inmost ,TPs are not met until the o8erall ,TP has the essential elements of DOT1
firmly in *lace
1.( methodo"ogy
De8elo*ment of the fourth edition of the guidelines follo9ed ne9 WHO *rocedures
WHO defined the sco*e of re8ision and con8ened a guidelines grou* of e@ternal
e@*erts (ll members of the grou* com*leted a Declaration for the Conflict of
/nterest; there 9ere no conflicts declared With in*ut from the .uidelines .rou*)
WHO identified se8en
-
8/8/2019 5_Guidelines TB.doc
31/161
1. InroduCIon
e8idence) 8alues) and costs) as 9ell as udgements about trade-offs bet9een benefits
and harm
The grou* graded the strength of each recommendation) reflecting the degree of
confidence that the desirable effects of adherence to a recommendation out9eigh the
undesirable effects (lthough the degree of confidence is necessarily a continuum)three categories are used – strong) conditional and 9ea(DB methodology 1!7
"oderate!lo9 ?uality of e8idence means that the estimate of effect of the
inter8ention is 8ery uncertain and further research is li
-
8/8/2019 5_Guidelines TB.doc
32/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
recommendation strength
Strong Conditiona"
hrasing of the
recommendation
>Shou"d? or >shou"d not?.
no alternatives are
presented
>o)tima" is?4 >may?4 or >it
is 6not7 recommended?.
Alternatives are often
listedfactors used to udge strength
9ualit& of evidence -igh9ualit& evidence low9ualit& evidence
,alance between
desirable and
undesirable effects on
patient and public
health
large4 certain net benefit
and@or difference between
benefits and harms or
burdens
8mall and@or uncertain
gradient
resource allocation low cost ;or little uncertaint&
about whether the
intervention represents a wise
use of resources<
-igh cost ;or high
uncertaint&<
uncertaint& in values
and preferences
variabilit& across
patients
8mall amount of uncertaint&
or variabilit&
large amount of
uncertaint& or variabilit&
Im)"ications
for )o"icy%ma8ers ;including nTp
managers<
The recommendation shouldune9uivocall& be used for
setting polic&
polic&making will re9uireextensive debate
for )atients most individuals would want
the recommended course of
action
The recommended
course of action can be
adjusted on the basis of
feasibilit& and
acceptabilit&for hea"th care
)roviders
most patients should be
treated according to the
recommended course of
action. Adherence to this
recommendation is areasonable measure of good
9ualit& care
The draft guidelines 9ere circulated to the e@ternal re8ie9 grou* 9hose members
are listed in (nne@ 67) made u* of ,TP managers from high-burden countries)
members of the WHO 1trategic) Technical and (d8isory .rou* on T# 1T(.-T#7)
si@ regional T# (d8isers and T# medical officers 9or
-
8/8/2019 5_Guidelines TB.doc
33/161
1. InroduCIon
1.* Internationa" Standards for u!ercu"osis Care
The -nternational tandards for Tuberculosis /are /1TC7 1"7 describe a 9idely
acce*ted le8el of T# care that all *ractitioners should see< to achie8e Cross-
referencing the a**licable /1TC standards in this ne9 edition should hel* *ro8iders
in both *ublic and *ri8ate sectors to ensure their im*lementation
1.+ Ex)iry date
The WHO 1to* T# De*artment 9ill re8ie9 and u*date these guidelines after +–
years or as needed 9hen ne9 e8idence) treatment regimens or diagnostic tests
become a8ailable
references' >a8iglione "C) I*le
-
8/8/2019 5_Guidelines TB.doc
34/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
'+ Bs*inal "( Time to abandon the standard retreatment regimen 9ith first-line
drugs for failures of standard treatment -nternational 4ournal of Tuberculosis and
0ung Disease) $%%+) 2:6%2–6%3
'4 .uyatt .H et al .>(DB: an emerging consensus on rating ?uality of e8idence
and strength of recommendations *ritis( Medical 4ournal ) $%%3) ++6:&$4–&$6
' -nternational tandards for Tuberculosis /are -T/;) $nd ed The Hague)Tuberculosis Coalition for Technical (ssistance) $%%&
2
2
-
8/8/2019 5_Guidelines TB.doc
35/161
Case definitions
2.1 Cha)ter o!ectives
This cha*ter describes
the *ur*ose of ha8ing case definitions for tuberculosis;
the definition of a case of T#) as 9ell as of sus*ected and confirmed cases;
additional features of T# cases im*ortant for the treatment of indi8idual
*atients) as 9ell as for e8aluating T# *rogrammes and monitoring the
e*idemic
The diagnosis of T# refers to the recognition by health 9or
-
8/8/2019 5_Guidelines TB.doc
36/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
2.3 Case definitions
The T# case definitions belo9 are based on the le8el of certainty of the diagnosis
and on 9hether or not laboratory confirmation is a8ailable
S Tu)erculosis suspect (ny *erson 9ho *resents 9ith sym*toms or signs
suggesti8e of T# The most common sym*tom of *ulmonary T# is a *roducti8ecough for more than $ 9ee
-
8/8/2019 5_Guidelines TB.doc
37/161
the lungs) constitutes a case of e=tra *ulmonary T# ( *atient 9ith both *ulmonary
and e@tra*ulmonary T# should be classified as a case of pulmonary T#
2. CaSE dEfInIIonS
&6trapulmonary tu)erculosis BPT#7 refers to a case of T# defined abo8e7in8ol8ing organs other than the lungs) eg *leura) lym*h nodes) abdomen)
genitourinary tract) s-T#
cases) see reference $
1tandard $ of the /1TC "7 states that all *atients sus*ected of ha8ing *ulmonary T#
should submit at least t9o s*utum s*ecimens for microsco*ic e@amination in a
?uality-assured laboratory When *ossible) at least one early-morning s*ecimen
should be obtained) as s*utum collected at this time has the highest yield /1TC
1tandard 4 states that all *ersons 9ith chest radiogra*hic findings suggesti8e of T#
should submit s*utum s*ecimens for microbiological e@amination "7
1mear-*ositi8e cases are the most infectious and most li
-
8/8/2019 5_Guidelines TB.doc
38/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
' /n countries 9ithout functional B() the definition from the third edition of these guidelines a**lies:
a smear-*ositi8e *ulmonary T# case 9as defined as one 9ith:
a t9o or more initial s*utum smear e@aminations *ositi8e for (5#) or
b one s*utum smear e@amination *ositi8e for (5# *lus radiogra*hic abnormalities consistent
9ith acti8e PT# as determined by a clinician) orc one s*utum smear *ositi8e for (5# *lus s*utum culture-*ositi8e for M. tuberculosis
mear)negative PT# cases should either:
( ha8e s*utum that is smear-negati8e but culture-*ositi8e for M. tuberculosis:
S a case of *ulmonary T# is considered to be smear)negative if at least t9o
s*utum s*ecimens at the start of treatment are negati8e for (5#' in countries
9ith a functional B( system) 9here the 9or
-
8/8/2019 5_Guidelines TB.doc
39/161
2.( &istory of )revious treatment: )atient registration grou)
(t the time of registration) each *atient meeting the case definition is also classified
according to 9hether or not he or she has *re8iously recei8ed T# treatment and) if
so) the outcome if
-
8/8/2019 5_Guidelines TB.doc
40/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
other B or All cases that do not fit the above
definitions4 such as patients
D for whom it is not known
whether the& have been
previousl& treated
D who were previousl& treated
but with unknown outcome of that
previous treatmentb ;34 8 other retreatment? in other w-o documents cited above.
2.* &I' status
Determining and recording the *atientAs H/E status is critical for treatment decisions
see Cha*ters + and 7 as 9ell as for monitoring trends and assessing *rogramme
*erformance WHOAs re8ised T# Treatment Card and T# >egister include dates of
H/E testing) starting co-trimo@a0ole) and starting (>T These im*ortant
inter8entions are discussed more fully in Cha*ter
references
' ?ngaging all (ealt( care providers in T* control: guidance on implementing
publicprivate mi= approac(es .ene8a) World Health Organi0ation) $%%6
WHO!HT"! T#!$%%6+6%7
$ @7> policy on T* infection control in (ealt( care facilities congregate
settings and (ouse(olds .ene8a) World Health Organi0ation) $%%&
WHO!HT"!T#!$%%&4'&7
+ -mplementing t(e @7> top T* trategy: a (andbook for national tuberculosis
control programmes .ene8a) World Health Organi0ation) $%%3
WHO!HT"!T#!$%%34%7
4 -mproving t(e diagnosis and treatment of smear)negative pulmonary and
e=trapulmonary tuberculosis among adults and adolescents: recommendations for
7-8)prevalent and resource)constrained settings .ene8a) World HealthOrgani0ation) $%%2 WHO! HT"!T#!$%%2+2&; WHO!H/E!$%%2'7
-nternational tandards for Tuberculosis /are -T/;) $nd ed The Hague)
Tuberculosis Coalition for Technical (ssistance) $%%&
6 Revised T* recording and reporting forms and registers , version 2''#
.ene8a) World Health Organi0ation) $%%6 WHO!HT"!T#!$%%6+2+; a8ailable at:
9999hoint! tb!dots!rUandUrUforms!en!inde@html7
2 6uidelines for t(e programmatic management of drug)resistant tuberculosis:
emergency update 2''% .ene8a) World Health Organi0ation) $%%3
WHO!HT"!T#! $%%34%$7
3 6lobal tuberculosis control 2''&: epidemiology strategy financing. @7>
report 2''& .ene8a) World Health Organi0ation) $%%& WHO!HT"!T#!$%%&4''7
3
3
0
-
8/8/2019 5_Guidelines TB.doc
41/161
standard treatment
regimens
3.1 Cha)ter o!ectives
This cha*ter describes:
the aims of treatment;
the recommended doses of first-line anti-T# drugs for adults;
regimens for ne9 and *re8iously treated *atients;
considerations in selecting regimens for defined *atient grou*s;
e8idence base for the selected regimens in defined *atient grou*sThe choice of T# regimens in s*ecial situations *regnancy) concurrent use of oral
contrace*ti8es) li8er disease) and renal failure7 is co8ered in Cha*ter 3; T# treatment
for *ersons li8ing 9ith H/E is discussed in Cha*ter
3.2 aims of treatment
The aims of treatment of tuberculosis are:
to cure the *atient and restore ?uality of life and *roducti8ity;
to *re8ent death from acti8e T# or its late effects; to *re8ent rela*se of T#;
to reduce transmission of T# to others;
to *re8ent the de8elo*ment and transmission of drug resistance
3.3 Essentia" antitu!ercu"osis drugs
Table +' sho9s the essential anti-T# drugs and their recommended dosages based
on the *atientAs 9eight
The WHO-recommended formulations of anti-T# drugs and fi@ed-dosecombinations 5DCs7 of drugs a**ear in the @7> Model 0ist of ?ssential
Medicines a8ailable at 9999hoint!medicines!*ublications!essentialmedicines!en7
The formulations and combinations of anti-T# drugs a8ailable in each country
should conform to this list 1ee also the WHO "odel 5ormulary at
9999hoint!selectionUmedicines!list! en7
To facilitate *rocurement) distribution and administration of treatment to *atients)
the daily dosage may be standardi0ed for three or four body 9eight bands – for
instance +%–+&
-
8/8/2019 5_Guidelines TB.doc
42/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
drug
recommended dose
dai"y 3 times )er ee8
dose and range
;mg@kg bod&weight<
maximum
;mg<
dose and range
;mg@kg bod&weight<
dai"y maximum
;mg<
isonia6id ;$(< #77 17 ;*1!< 077
rifampicin 17 ;*1!< (77 17 ;*1!< (77
p&ra6inamide ! ;!7#7< # ;#7$7<
ethambutol 1 ;1!7< #7 ;!#<
8treptom&cina 1 ;1!1*< 1 ;1!1*< 1777
a patients aged over (7 &ears ma& not be able to tolerate more than 77+7 mg dail&4 so some
guidelines recommend reduction of the dose to 17 mg@kg per da& in patients in this age group
;2
-
8/8/2019 5_Guidelines TB.doc
43/161
acce*tability and to@icity of a four-drug 5DC com*ared 9ith loose *ills gi8en in the
intensi8e *hase
3
1
-
8/8/2019 5_Guidelines TB.doc
44/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
of treatment has ust been com*leted and results should soon be a8ailable (nother
multicentre study including *harmaco
uality assurance is essential to ensure ade?uate bioa8ailability of the com*onentdrugs of 5DCs' Ising 5DCs does not ob8iate the need for se*arate drugs for
*atients 9ho de8elo* drug to@icity or intolerance or for those 9ith contraindications
to s*ecific com*onent drugs
#.#.! patient kits
( T# *atient
-
8/8/2019 5_Guidelines TB.doc
45/161
3. Sandard rEamEn rE#ImEnS
>ecommended regimens for different *atient registration grou*s are sho9n in Tables
+$) ++ and +4 "ore details on the e8idence and udgements underlying the
recommended regimens are described in (nne@ $
3.5 ne )atients
,e9 *atients are defined as those 9ho ha8e no history of *rior T# treatment or 9ho
recei8ed less than ' month of anti-T# drugs regardless of 9hether their smear or
culture results are *ositi8e or not7 see section $67
#..1 new patients presumed or known to have drugsusceptible T,
,e9 *atients are *resumed to ha8e drug-susce*tible T# 9ith t9o e@ce*tions:
S Where there is a high *re8alence of isonia0id resistance in ne9 *atientssee section +$7
or
S /f they ha8e de8elo*ed acti8e T# after GB!4H>7 $ 7 WHO therefore
recommends the follo9ing for ne9 *atients *resumed or
-
8/8/2019 5_Guidelines TB.doc
46/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
1trong!High grade of e8idence7
/n terms of dosing fre?uency for H/E-negati8e *atients) the systematic re8ie9 found
little e8idence of differences in failure or rela*se rates 9ith daily or three times
9ee
-
8/8/2019 5_Guidelines TB.doc
47/161
3. Sandard rEamEn rE#ImEnS
There is insufficient e8idence to su**ort the efficacy of t9ice 9ee
-
8/8/2019 5_Guidelines TB.doc
48/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
rifam*icin regimen $ 7 The global 9eighted mean of any isonia0id resistance
e@cluding "D>7 is 24R in ne9 *atients %7 Thus) a significant *ro*ortion of the
ne9 T# cases in many regions of the 9orld ha8e a ris< of *oor treatment outcomes
because of their *retreatment isonia0id resistance
The follo9ing 9ea< recommendation a**lies to countries 9here isonia0id
susce*tibility testing in ne9 *atients is not done or results are not a8ailable7 before
the continuation *hase begins
L Recommendation
3n populations with -nown or suspected high le!els o# isoniazid resistance*
new T patients may recei!e HR& as therapy in the continuation phase as an
accepta)le alternati!e to HR
Wea
.i8en the *otential benefit &7 and lo9 ris< of to@icity from ethambutol) the *ressing
need to *re8ent "D> 9arrants this recommendation Ho9e8er) the recommendation
is conditional) for the reasons e@*lained in more detail in (nne@ $ The most
effecti8e regimen for the treatment of isonia0id-resistant T# is not
-
8/8/2019 5_Guidelines TB.doc
49/161
3. Sandard rEamEn rE#ImEnS
3.( revious"y treated )atients and mu"tidrug resistance
Pre8ious T# treatment is a strong determinant of drug resistance 1'7) and
*re8iously treated *atients com*rise a significant *ro*ortion '+R7 of the global T#
notifications in $%%2Of all the forms of drug resistance) it is most critical to detect multidrug resistance
"D>7 because it ma treatment 9ith second-line drugs gi8es a better chance of cure and *re8ents
the de8elo*ment and s*read of further resistance #ecause of its clinical
significance) "D> rather than any drug resistance7 is used to describe the
retreatment *atient grou*s belo9
(t the global le8el) 'R of *re8iously treated *atients ha8e "D> %7) 9hich is fi8etimes higher than the global a8erage of +R in ne9 *atients 5igure +'7 B8en in
(frica) the WHO region thought to ha8e the lo9est le8el of "D> in retreatment
*atients) a significant *ro*ortion 6R7 of retreatment *atients ha8e "D>-T# %7' /f
their "D> is not detected and treated 9ith second-line drugs) these *atients 9ill
suffer *oor outcomes and s*read "D> in their communities
WHO sur8eillance data from '% countries found the le8el of "D> to be +$R in
*atients returning after defaulting or rela*sing and significantly higher 4&R7 in
*atients 9hose *rior treatment has failed 5igure +$7$ Other studies sho9 "D>
le8els of u* to 3%–&%R in *atients 9hose *rior treatment courses ha8e failed 1',
1# 7 "odelling described in (nne@ $ *redicts that) 9hen a first course of treatment
containing 6 months of rifam*icin fails) %–&4R of *atients ha8e "D>-T#
com*ared 9ith 4–6R of *atients u*on failure of a regimen containing $ months of
rifam*icin7
"any factors influence the le8el of "D> in *re8iously treated *atients) and le8els
are li
-
8/8/2019 5_Guidelines TB.doc
50/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
0! 7* casesb 1* *+# casesc
a 8ource Anti-tuberculosis
drug resistance in the orld! "ourthglobal re#ort . geneva4 world -ealth
organi6ation ;!77*< ;8
-
8/8/2019 5_Guidelines TB.doc
51/161
3. Sandard rEamEn rE#ImEnS
identify "D> as early as *ossible so that a**ro*riate treatment can be gi8en 1ee
also 1tandard '' of the /1TC 77
L Recommendation ;.1
:pecimens #or culture and drug suscepti)ility testing /9:T should )eo)tained #rom all pre!iously treated T patients at or )e#ore the start o#
treatment. 9:T should )e per#ormed #or at least isoniazid and ri#ampicin
The a**roach to the initiation of retreatment de*ends on the countryAs laboratory
ca*acity) s*ecifically w(en or if7 D1T results are routinely a8ailable for the
indi8idual *atient Countries using ra*id molecular-based D1T 1%) 1&7 9ill ha8e
results for rifam*icin!isonia0id a8ailable 9ithin '–$ days; these results can be used
in deciding 9hich regimen to start for the indi8idual *atient section +2'7
Ising con8entional D1T methods yields results 9ithin 9ee
regimen Drug resistance sur8eillance or sur8eys often sho9 that those rela*sing or
returning after default ha8e a medium or lo9 li in
different *atient registration grou*s 8ary by setting'
/t must be noted) ho9e8er) that the retreatment regimen using first-line drugs is not
su**orted by e8idence deri8ing from clinical trials /t 9as designed *rimarily for usein settings 9ith lo9 *re8alence of initial drug resistance and in *atients *re8iously
treated 9ith a regimen that included rifam*icin for the first $ months 2'7
The assum*tion that *atients 9hose treatment has failed ha8e a high li7 may
need to be modified according to both the le8el of "D> found in these *atient
registration grou*s and the considerations discussed in section +3 belo97
' /f drug resistance sur8eys sho9 that *atients rela*sing or returning after default ha8e high le8els of "D>) they 9ill need an "D> regimen instead 1imilarly) if the country data sho9 that le8els of "D>
are lo9 in *atients 9ho failed their *re8ious treatment) the ,TP may decide to administer retreatment
regimens 9ith first-line drugs 1ee section +3 for further details
5
3
-
8/8/2019 5_Guidelines TB.doc
52/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
1e8eral other considerations also described in section +37 9ill ha8e an im*act on
the le8el of "D> the ,TP designates as MhighN in a gi8en country 1ee also
1tandard '$ of the /1TC 77
Countries 9ill need to use a mi@ of a**roaches if they are in transition) 9here someareas of the country do not yet ha8e D1T results routinely a8ailable and others do) or
some laboratories use ra*id and others con8entional D1T methods
#.+.1 previousl& treated patients in settings with rapid d8T
With line *robe assays) "D> can be essentially confirmed ' or e@cluded 9ithin '–$
days)$ 9hich allo9s the results to guide the regimen at the start of thera*y
L Recommendation ;.2
3n settings where rapid molecular5)ased 9:T is a!aila)le* the results shouldguide the choice o# regimen
The use of ra*id molecular-based tests is discussed in more detail in section +3'
belo9
#.+.! previousl& treated patients in settings where conventional d8T results
are routinel& available for individual patients
Obtaining s*ecimens for con8entional culture and D1T should not delay the start of
thera*y Bm*irical regimens) often based on drug-resistance sur8eillance data) areused 9hile the results of con8entional D1T li?uid or solid media7 are a9aited) and
should be started *rom*tly+ This is es*ecially im*ortant if the *atient is seriously ill
or the disease is *rogressing ra*idly Placing a *atient on an em*iric regimen
*ending D1T is done to a8oid clinical deterioration (lso) once em*iric thera*y
begins to render the *atient less infectious) the ris< of transmission to contacts
decreases
While a9aiting the results of con8entional D1T) WHO recommends administering
an em*iric "D> regimen4 for *atient grou*s 9ith a high li Table +47
' Line *robe assays detect resistance to rifam*icin alone or in combination 9ith isonia0id resistance
O8erall high accuracy for detection of "D> is retained 9hen rifam*icin resistance alone is used as a
mar regimen is *ro8ided in Cha*ter 2 of this document)
and in Cha*ter 2 of 6uidelines for t(e programmatic management of drug)resistant T* # 7
5
2
-
8/8/2019 5_Guidelines TB.doc
53/161
3. Sandard rEamEn rE#ImEnS
L Recommendation ;.
3n settings where rapid molecular5)ased 9:T results are not routinely
a!aila)le to guide the management o# indi!idual patients* empiric treatment
should )e started as #ollows$
L Recommendation ;..1
T patients whose treatment has failed 1 or other patient groups with high
li-elihood o# multidrug5resistant T /-T# are
those rela*sing or defaulting after their second or subse?uent course of treatment 1ee also section +3$
L Recommendation ;..2
T patients returning a#ter defaulting or relapsing #rom their #irst
treatment course may recei!e the retreatment regimen containing #irst5
line drugs 2HR%&:'1HR%&'8HR& i# country5speci#ic data show low or
medium le!els o# -T# in *re8iously treated *atients) by using data from a drug resistance
sur8ey) from a national or su*ranational reference laboratory) or from a referral or
research centre see section +3$7 These data are critical for ascertaining the le8el
' 5ailures in a 9ell-run ,TP should be infre?uent in the absence of "D>-T# /f they do occur) they are
due either to "D>-T# or to *rogramme factors such as *oor DOT or *oor drug ?uality /f drugresistance data from failure *atients are a8ailable and these sho9 lo9 or medium le8els of "D>) *atients should recei8e the retreatment regimen outlined in 2+$) and e8ery effort should be made toaddress the underlying *rogrammatic issues
5
3
-
8/8/2019 5_Guidelines TB.doc
54/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
of "D> in retreatment *atients' 5or e@am*le) the results of re*resentati8e drug
resistance sur8eys may identify a grou* of *atients among 9hom a 8ery high
*ercentage ha8e "D>) 9hich could ustify the use of "D> regimens in all *atients
in the grou* e8en if indi8idual D1T is not a8ailable7 # 7 The ,TP manager is
encouraged to obtain technical assistance from the .reen Light Committee see
section +3+7
/f a 8ery high le8el of "D> is documented in a s*ecific grou* such as *atients 9ho
ha8e failed a retreatment regimen7) the ,TP manager should urgently see< means to
routinely obtain D1T on all such *atients at the start of treatment) in order to confirm
or e@clude "D> /f this cannot yet be achie8ed 9ith any in-country laboratory)
,TPs should ma-
T# regimen 9hile a9aiting confirmation of isonia0id and rifam*icin resistance last
ro9 of Table +47 # 7 This is a temporary measure that can be im*lemented only if
culture and D1T can be arranged in the first fe9 months of "D> treatment in each
enrolled *atient /t is essential to confirm the *resence of "D>) and to monitor theres*onse to treatment .rou*s of *atients 9hose li
-
8/8/2019 5_Guidelines TB.doc
55/161
3. Sandard rEamEn rE#ImEnS
Mne9 *atient regimenN: the regimen containing 6 months of rifam*icin:
$H>GB!4H> '
Mretreatment regimen 9ith first-line drugsN: $H>GB1!'H>GB!H>B$
M"D> regimenN
To im*lement these regimens in the country) the ,TP needs to consider the
follo9ing factors:
a8ailability of results of con8entional or ra*id molecular-based D1T to guide
management of indi8idual *atients;
le8el of drug resistance in the countryAs ne9 and *re8iously treated *atients;
number of "D>-T# *atients the *rogramme has the ca*acity to enrol and
treat;
the short-term ris< of dying from "D>-T# due to concomitant conditionses*ecially H/E) discussed in Cha*ter 7;
a8ailability of *atient su**ort and su*er8ision discussed in Cha*ter 67
"any of these factors de*end on a8ailable resources in the country) *articularly the
a8ailability of D1T and "D>-T# treatment #ecause these essential elements of the
1to* T# 1trategy are not yet fully in *lace throughout the 9orld) this cha*ter
*ro8ides guidance on interim a**roaches
Table +4 belo9 *resents suggestions for ho9 the ,TP manager can ta *re8alence /t is essential to detect
"D> as soon as *ossible in *ersons li8ing 9ith H/E) gi8en their high ris< of
mortality Table #.$ 8TAndArd regimen8 for pre/iou8l& TreATed
pATienT8 depending on the availabilit& of routine d8T to guide the
therap& of individual retreatment patients
' With or 9ithout ethambutol in the continuation *hase see section +$7
$ Countries 9ith ra*id molecular-based D1T 9ill not need this regimen
5
3
-
8/8/2019 5_Guidelines TB.doc
56/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
dS "i8e"ihood of mdr 6)atient registration grou)a7
routinel& available for
previousl& treated
patients
-igh ;failureb< medium or low ;relapse4
default<
rapid molecularbased
method
d8T results available in 1! da&s confirm or exclude mdr
to guide the choice of regimen
conventional method while awaiting d8T resultsc
empirical mdr regimen !-r:e8@-r:e@-re
%egimen should be modi"ied %egimen should be
modi"ied once $*' results are a&ailable. once $*'
results are a&ailable.
none ;interim< empirical mdr regimen !-r:e8@-r:e@-re for full
%egimen should be modi"ied course of treatment.
once $*' results or $%* data %egimen should be
modi"ied
are a&ailable. once $*' results or $%* data
are a&ailable.a The assumption that failure patients have a high likelihood of mdr ;and relapse or defaulting
patients a medium likelihood< ma& need to be modified according to the level of mdr in these
patient registration groups4 as well considerations discussed in section #.*. b And other patients
in groups with high levels of mdr. one example is patients who develop active T, after known
contact with a patient with documented mdrT,. patients who are relapsing or returning after
defaulting from their second or subse9uent course of treatment probabl& also have a high
likelihood of mdr.c regimen ma& be modified once d8T results are available ;up to !# months after the start of
treatment-T#
S (ll ne9 *atients in countries 9here the le8el of "D>-T# in ne9 *atients is
+R
5
2
-
8/8/2019 5_Guidelines TB.doc
57/161
3. Sandard rEamEn rE#ImEnS
27
/n addition to the indications listed abo8e for D1T at t(e start of treatment or
retreatment7) WHO recommends that D1T be *erforming during treatment in the
follo9ing situation:
S ,e9 and *re8iously treated *atients 9ho remain s*utum smear-*ositi8e at
the end of the intensi8e *hase should submit another s*ecimen for smear
microsco*y the follo9ing month /f that s*ecimen is also smear-*ositi8e) culture
and D1T should be undertaecommendation + in Cha*ter 47 This 9ill
allo9 a result to be a8ailable earlier than the fifth month of treatment
Com*rehensi8e systems for managing the ?uality of laboratory ser8ices) including
internal ?uality control and e@ternal ?uality assurance) are mandatory Laboratories
should follo9 standardi0ed *rotocols for good laboratory *ractice) technical *rocedures and biosafety) in com*liance 9ith international standards # 7
Documentary *roof of sustained technical *roficiency in D1T is essential) and lin and
am*lification of resistance to include ethambutol
S With em*irical use of "D> regimens) *atients 9hose D1T e8entually rules
out "D> 9ill ha8e been e@*osed to to@ic drugs they did not need 9hile a9aitingD1T results Conse?uences could include ad8erse drug effects and an increased
ris< of defaulting from treatment
' 1ee 9999hoint!tb!dots!laboratory!*olicy!en!inde@+html
5
3
-
8/8/2019 5_Guidelines TB.doc
58/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
%a#id $*'
/n contrast to con8entional methods) molecular-am*lification assays such as line
*robe assays allo9 detection of rifam*icin resistance alone or in combination 9ith
isonia0id7 9ithin days of s*utum s*ecimens being obtained from the *atient and can
also be used on cultures obtained from ra*id li?uid culture systems7 Patients 9ith
"D>-T# can a8oid delays in starting an "D> regimen) and T# *atients 9ithout
"D> 9ill a8oid unnecessary second-line drug treatment WHO strongly encourages
the use of ra*id molecular and culture-based7 D1T in smear-*ositi8e *ersons li8ing
9ith H/E # 7
WHO recommends that ministries of health decide on line *robe assays for ra*id
detection of "D>-T# 9ithin the conte@t of country *lans for a**ro*riate
management of "D>-T# *atients; *lans should also include the de8elo*ment of
country-s*ecific screening algorithms and timely access to ?uality-assured second-line anti-T# drugs 2!7
Line *robe assays ha8e been ade?uately 8alidated in direct testing of s*utum
smear*ositi8e s*ecimens) as 9ell as on isolates of M. tuberculosis com*le@ gro9n
from smear-negati8e and smear-*ositi8e s*ecimens Direct use of line *robe assays
on smear-negati8e clinical s*ecimens is not recommended (do*tion of line *robe
assays does not eliminate the need for con8entional culture and D1T ca*ability;
culture remains necessary for definiti8e diagnosis of T# in smear-negati8e *atients)
9hile con8entional D1T is re?uired to determine drug susce*tibility to drugs other than rifam*icin and isonia0id (dditional guidance on selecting and im*lementing
ra*id drug susce*tibility tests can be found on the WHO 9eb site at:
9999hoint!tb! featuresUarchi8e!mdrtbUra*idUtests!en!inde@html
#.*.! level of drug resistance in the countr&3s new and previousl& treated
patients Countries re*orting a**ro@imately half the 9orldAs T# cases ha8e
conducted at least one drug resistance sur8ey since '&&4 %7 These results) together
9ith estimates of "D>-T# le8els in all countries) are a8ailable on the WHO 9eb
site at: 9999hoint! tb!featuresUarchi8e!drsre*ortUlaunchU$6feb%3!en!inde@html
Ne #atients
Drug resistance information is critical for managing ne9 *atients and selecting the
countryAs standard regimen for ne9 *atients:
S /f country data or WHO estimates7 sho9 that more than +R of ne9
*atients ha8e "D>) D1T should be obtained at the start of thera*y for all ne9
*atients see section +3'7
S "any countries ha8e a high le8el of isonia0id resistance in ne9 *atients butdo not ha8e drug susce*tibility results for isonia0id by the time of the
continuation *hase /n these countries) the ,TP may select an
5
2
-
8/8/2019 5_Guidelines TB.doc
59/161
3. Sandard rEamEn rE#ImEnS
isonia0id!rifam*icin!ethambutol continuation *hase for the standard regimen to be
used for all ne9 *atients) as discussed in section +$
,re&iously treated #atients(s discussed in section +6 abo8e) the ,TP needs to re8ie9 country-s*ecific data to
8erify) or modify) the assignment of failure *atients to high li #o@es +') +$ and ++ *ro8ide e@am*les of ho9 these data may
be used While WHO recommends that D1T be *erformed on all *re8iously treated
cases 227) systems that 9ill yield this critical information are not yet in *lace in
most countries Intil countries ha8e finished establishing the needed laboratory and
sur8eillance ca*acity) information on the le8el of "D> in *re8iously treated *atients
is a8ailable from a fe9 other sources
The .lobal Drug >esistance 1ur8eillance *roect includes actual and estimated
le8els of "D> in *re8iously treated *atients as a 9hole) although sam*le si0es 9ere
usually too small to yield 8ery *recise estimates %7 "oreo8er) only '% countries
ha8e measured "D> le8els in subgrou*s of *re8iously treated *atients since '&&4
5igure +$7
(lternati8e sources of data are in-country laboratories) su*ranational reference
laboratories) hos*itals) treatment centres and research *roects The results must be
inter*reted 9ith caution) as they re*resent only those *atients 9ho ha8e accessed thes*ecific ser8ices and those institutions 9here the testing is done 5or e@am*le) the
le8el of "D> found in a hos*ital-based sur8ey in a ca*ital city acce*ting referrals of
the most difficult cases is li
-
8/8/2019 5_Guidelines TB.doc
60/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
Note on other #atient-s#eci"ic ris "actors "or M$%
#y assigning registration grou*s of *re8iously treated *atients to high and medium
li-T# is *rior T# treatment 1)
1!7
Jno9n contact 9ith a *ro8en "D> case is another im*ortant determinant and can
be ascertained by T# *rogrammes at the time of *atient registration Other T#
*atients obser8ed to ha8e ele8ated "D> le8els in certain settings are those # 7:
treated in a *rogramme that o*erates *oorly;
9ith a history of using anti-T# drugs of *oor or un
such as certain *risons or mines7;
9ith co-morbid conditions associated 9ith malabsor*tion or ra*id-transit
diarrhoea;
li8ing 9ith H/E in some settings7;
9hose *rior course of thera*y included rifam*icin throughout (nne@ $7; ha8e ty*e $ diabetes mellitus 2"7
,TPs may be able to collect sam*les for D1T from some of the *atient grou*s listed
abo8e to determine their le8els of "D>
#.*.# number of mdrT, patients the programme has the capacit& to enrol
The .reen Light Committee .LC7 /nitiati8e hel*s countries to gain access to
?ualityassured second-line drugs' at considerably less than mar detection and treatment can a**ly to the .lobal 5und
to 5ight (/D1) Tuberculosis and "alaria or other donors for funding
' /f second-line drugs are used) the ,TP must ensure that they are ?uality-assured and can be *ro8ided by DOT throughout the entire '3–$4 months it ta
-
8/8/2019 5_Guidelines TB.doc
61/161
3. Sandard rEamEn rE#ImEnS
ox 3.2
5
3
-
8/8/2019 5_Guidelines TB.doc
62/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
An exAmple of A88igning T-e pATienT group wiT-
T-e -ig-e8T mdr le/el8 To recei/e empiricAl mdr TreATmenT4
And lATer Adding A pATienT group wiT- T-e nexT -ig-e8T mdr
le/el84 during 8cAleup of mdrT, TreATmenT,ased on a special surve& in one province4 countr& , finds an mdr level of 07I
in T, patients whose treatment failed after two or more prior courses. for
patients whose first treatment course failed4 the level is (7I. The T, patients in
this province are roughl& representative of the whole countr&3s T, patients. in
countr& ,4 d8T of isonia6id and rifampicin is done routinel& for individual
patients whose previous treatment has failed but results are t&picall& not
available for $ months.
countr& , has just begun a green light committee initiative project and has the
capacit& to treat a ver& limited number of mdrT, patients. it recommends thatpatients whose second or subse9uent course of treatment has failed be
managed as patients with a high likelihood of mdr ;as recommended in Table
#.$< and receive an empirical regimen for mdr while d8T results are awaited.
until the mdr programme is scaled up further4 patients whose first treatment
course has failed will be managed as those with a medium likelihood of mdr.
empiricall&4 the& all start the retreatment regimen with firstline drugs. when d8T
results are available $ months later4 those confirmed as having mdrT, are
changed to the mdr regimen.
Two &ears later4 another drug resistance surve& continues to show that (7I of patients whose first treatment failed have mdr4 and their outcomes have been
poor when treated empiricall& with the retreatment regimen of firstline drugs for
the $ months it takes to obtain d8T results. ,& contrast4 treatment with the
countr&3s standard mdr regimen is having good success in the patients in whom
two or more prior treatment courses have failed. The countr& applies for and
receives additional support from the global fund to now use empirical mdr
regimens ;while awaiting d8T results< for patients whose first treatment course
has failed.
(s sufficient funding becomes a8ailable) countries 9ill *ro8ide uni8ersal access to
"D>-T# treatment The stage of im*lementation has a bearing on the le8el of "D> that the country 9ill use to define MhighN) MmediumN and Mlo9N li *rogramme) 9hen the a8ailability of "D> treatment is
8ery limited) the ,TP may chose to include only the 8ery highest ris< *atients in the
Mhigh li treatment 9hile D1T results
are a9aited (s the *rogramme is scaled u*) the ,TP manager can include more
*atients 9ho need "D> treatment Thus) there are no absolute thresholds for lo9)
moderate) or high li-T# treatment
ox 3.3
5
2
-
8/8/2019 5_Guidelines TB.doc
63/161
3. Sandard rEamEn rE#ImEnS
An exAmple of weig-ing T-e -Arm8 And ,enefiT8 of empiricAl
mdr
TreATmenT in A 8eTTing of -ig- -i/ pre/Alence
in countr& c4 *7I of all T, patients are living with -i/4 and #7I of relapsepatients have mdr. while the countr& is planning to implement rapid d8T4 it takes
an average of ! months to obtain results using the current conventional
methods. The nTp is deciding which empirical regimen to include in the nTp
manual for relapse patients for the ! months it takes to obtain d8T results.
given the high level of -i/ and the attendant risks of earl& death from untreated
mdrT,4 the nTp decides to recommend that all relapse patients be treated with
the countr&3s empirical mdr regimen while d8T results are awaited. The benefit
of preventing earl& deaths in the #7I of relapse patients who do have mdr is
judged to be greater than the possible harmsa
of mdr treatment ;during the !months awaiting d8T results< in the +7I of relapse patients who will prove to
not have mdr.
a possible harms include drug toxicit&4 increased likelihood of patient default4 and burden
on patient and programme resources.
#.*.$ 8hortterm risk of death from mdrT,
Clinicians faced 9ith a 8ery ill T# *atient sus*ected of ha8ing "D>-T# 9ill initiate
an "D> regimen 9hile D1T results are *ending) e8en if the li regimen is out9eighed by the *ossible life-sa8ing benefit of the "D> regimen
1imilar udgements a**ly to regimen decisions at the le8el of the ,TP /f *re8iously
treated *atients as a grou* ha8e fre?uent concomitant conditions such as H/E7 that
increase the ris< of short-term death from "D>-T#) the ,TP 9ill 9ant to
recommend an em*irical "D> regimen for more retreatment *atients 9hile D1T
results are a9aited WHO also recommends the use of ra*id molecular-based tests
in smear-*ositi8e *ersons found to be li8ing 9ith H/E) as 9ell as culture-based D1T
to determine additional drug susce*tibility # 77
#.*. Availabilit& of patient support and supervision
The a8ailability of good ?uality *atient su**ort and su*er8ision is essential to
im*lementation of the regimens recommended in this cha*ter The im*ortance of the
ca*acity of T# *rogrammes to *ro8ide *atient-centred care is discussed in Cha*ter
6
references
' >ational Pharmaceutical "anagement Plus Program Managing
p(armaceuticals and commodities for tuberculosis: a guide for national tuberculosis
programs (rlington) E() "anagement 1ciences for Health) $%%
5
3
-
8/8/2019 5_Guidelines TB.doc
64/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
$ (merican Thoracic 1ociety) CDC) /nfectious Diseases 1ociety of (merica
Treatment of tuberculosis Morbidity and Mortality @eekly Report:
Recommendations and Reports) $%%+) $>>-''7:'–22
+ -nternational tandards for Tuberculosis /are -T/;) $nd ed The Hague)
Tuberculosis Coalition for Technical (ssistance) $%%&4 Connor ) >after ,) >odgers ( Do fi@ed-dose combination *ills or unit-of-use
*acrganiAation) $%%4) 3$:&+–&+&
#artace< ( et al Com*arison of a four-drug fi@ed-dose combination regimen
9ith a single tablet regimen in smear-*ositi8e *ulmonary tuberculosis -nternational
4ournal of Tuberculosis and 0ung Disease) $%%&) '+:26%–266
6 6uidelines for t(e programmatic management of drug)resistant tuberculosis:
emergency update 2''% .ene8a) World Health Organi0ation) $%%3 WHO!HT"!
T#!$%%34%$72 "en0ies D et al Bffect of duration and intermittency of rifam*in on
tuberculosis treatment outcomes: a systematic re8ie9 and meta-analysis lo
Medicine) $%%&) 6:e'%%%'46
3 5nti)tuberculosis drug resistance in t(e world: fourt( global report .ene8a)
World Health Organi0ation) $%%3 WHO!HT"!T#!$%%3+&47
& "itchison D( #asic mechanisms of chemothera*y /(est ) '&2&) 266 1u**l7:
22'– 23'
'% Bs*inal "( et al Determinants of drug-resistant tuberculosis: analysis of ''
countries -nternational 4ournal of Tuberculosis and 0ung Disease ) $%%') :332–
3&+
'' Bs*inal "( et al 1tandard short-course chemothera*y for drug-resistant
tuberculosis: treatment outcomes in 6 countries 4ournal of t(e 5merican Medical
5ssociation) $%%%) $3+:$+2–$4
'$ uy HT et al Drug resistance among failure and rela*se cases of tuberculosis:
is the standard re-treatment regimen ade?uate -nternational 4ournal of
Tuberculosis and 0ung Disease) $%%+) 2:6+'–6+6
'+ 1ara8ia C et al >etreatment management strategies 9hen first-line
tuberculosis thera*y fails -nternational 4ournal of Tuberculosis and 0ung Disease)
$%%) &:4$'– 4$&'4 oshiyama T et al De8elo*ment of ac?uired drug resistance in recurrent
tuberculosis *atients 9ith 8arious *re8ious treatment outcomes -nternational
4ournal of Tuberculosis and 0ung Disease) $%%4) 3:+'–+3
' Drobnie9sussia 4ournal of t(e 5merican Medical
5ssociation) $%%) $&+:$2$6–$2+'
'6 5austini () Hall () Perucci C( >is< factors for multidrug resistant
tuberculosis in Buro*e: a systematic re8ie9 T(ora=) $%%6) 6':'3–'6+
'2 T(e 6lobal lan to top T* 2''#,2'1" .ene8a) World Health Organi0ation)
$%%6 WHO!HT"!1T#!$%%6+7
'3 #arnard " et al >a*id molecular screening for multidrug-resistant tuberculosis
in a high-8olume *ublic health laboratory in 1outh (frica 5merican 4ournal of
Respiratory and /ritical /are Medicine) $%%3) '22:232–2&$
5
2
-
8/8/2019 5_Guidelines TB.doc
65/161
3. Sandard rEamEn rE#ImEnS
'& 1am /C et al "ycobacterium tuberculosis and rifam*in resistance) Inited
Jingdom ?merging -nfectious Diseases) $%%6) '$:2$–2&
$% "en0ies D et al 1tandardi0ed treatment of acti8e tuberculosis in *atients 9ith
*re8ious treatment and!or 9ith mono-resistance to isonia0id: a systematic re8ie9
and meta-analysis lo Medicine) $%%&) 6:e'%%%'%$' T(e global MDR)T* 9 +DR)T* response plan 2''$,2''% .ene8a) World
Health Organi0ation) $%%2 WHO!HT"!T#!$%%2+327
$$ 6uidelines for t(e surveillance of drug resistance in tuberculosis) 4th ed
.ene8a) World Health Organi0ation) $%%& WHO!HT"!T#!$%%&4$$7
$+ Bs*inal ") >a8iglione "C 5rom threat to reality: the real face of multidrug-
resistant tuberculosis 5merican 4ournal of Respiratory and /ritical /are Medicine)
$%%3) '23:$'6–$'2
$4 Molecular line probe assays for rapid screening of patients at risk of MDR T*:
policy statement .ene8a) World Health Organi0ation) $%%3 a8ailable at:9999hoint!tb! featuresUarchi8e!*olicyUstatement*df7
$ 5isher-Hoch 1P et al Ty*e $ diabetes and multidrug-resistant tuberculosis
candinavian 4ournal of -nfectious Diseases) $%%3) 4%:333–3&+
5
3
-
8/8/2019 5_Guidelines TB.doc
66/161
-
8/8/2019 5_Guidelines TB.doc
67/161
)onitoring during
treatment
$.1 Cha)ter o!ectives
This cha*ter describes ho9 to:
monitor and record the res*onse to treatment) and decide on actions to ta
-
8/8/2019 5_Guidelines TB.doc
68/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
figure $.1 8puTum moniToring ,& 8meAr micro8cop& in new pulmonAr& T,
pATienT8Note if a patient is found to harbour a multidrugresistant strain of T, at an& time during
therap&4 treatment is declared a failure and the patient is reregistered and should be referred to
an mdrT, treatment programme.
months of treatment
1 2 3 $ 5 (
J K
D
J
D a if sm B4 obtain
culture4 d8Tb
K
D a if sm B4 obtain
culture4 d8Tb
if smearpositive at month !4 obtain sputum again at month #. if smearpositive at
month #4 obtain culture and d8T. J K J K
D D D D ;sm B< if sm B4 obtain if sm B4 obtain if sm B4 obtain culture4
d8T culture4 d8Tb culture4 d8Tb
=e&
JK intensive phase of treatment ;-r:e<
JK continuation phase ;-r<
D 8putum smear examination sm B 8mearpositive a omit if patient was
smearnegative at the start of treatment and at ! months.b
8mear or culturepositivit& at the fifth month or later ;or detection of mdrT, at an& point< is defined
as treatment failure and necessitates reregistration and change of treatment as
described in section #.+.
figure $.! 8puTum moniToring of pulmonAr& T, pATienT8 recei/ing T-e *
monT- reTreATmenT regimen wiT- fir8Tline drug8
months of treatment
1 2 3 $ 5 ( * +
J K
D if smB4
obtain
culture4
d8T
JD
if sm B4obtain
culture4
d8Ta
K
D if sm B4obtain
culture4
d8Ta
=e&
JK intensive phase ! months of -r:e8 followed b& 1 month of -r:e
JK continuation phase with months of -re
D 8putum smear examination
sm B 8mearpositivea 8mear or culturepositivit& at the fifth month or later ;or detection of mdrT, at an& point< is
defined as treatment failure and necessitates reregistration and change of treatment as
described in section #.+.
6
6
-
8/8/2019 5_Guidelines TB.doc
69/161
$. monIorIn# durIn# rEamEn
This recommendation a**lies both to ne9 *atients treated 9ith regimens containing
6 months of rifam*icin $H>GB!4H>7 and to *re8iously treated *atients recei8ing
the 3-month retreatment regimen 9ith first-line drugs $H>GB1!'H>GB!H>B7
1*utum should be collected 9hen the *atient is gi8en the last dose of the
intensi8e*hase treatment The end of the intensi8e *hase is at $ months in ne9
*atients and + months in *re8iously treated *atients recei8ing the 3-month regimen
of first-line drugs This recommendation also a**lies to smear-negati8e *atients
1*utum s*ecimens should be collected for smear e@amination at each follo9-u*
s*utum chec(DB tables are
a8ailable from WHO u*on re?uest
6
5
-
8/8/2019 5_Guidelines TB.doc
70/161
rEamEn of u!ErCu"oSIS: #uIdE"InES
L Recommendation 8.2
3n new patients* i# the specimen o)tained at the end o# the intensi!e phase
/month 2 is smear5positi!e* sputum smear microscopy should )e o)tained at
the end o# the third month
1trong!High grade of e8idence7L Recommendation 8.
3n new patients* i# the specimen o)tained at the end o# month is smear5
positi!e* sputum culture and drug suscepti)ility testing /9:T should )e
per#ormed 1trong!High grade of e8idence7
The main *ur*ose of obtaining cultures at this stage is to detect drug resistance
9ithout 9aiting until the fifth month to change to a**ro*riate thera*y ' ,ote that
treatment is declared a failure if a *atient is found to harbour "D>-T# at any *oint
in time during treatment; see Table 4'7
/f the country does not yet ha8e sufficient laboratory ca*acity for culture and D1T)
additional monitoring of *atients 9ho are still smear-*ositi8e at month + 9ill be only
by s*utum smear microsco*y during the fifth month and during the final month of
treatment /f either result is *ositi8e) treatment has failed) the *atient is reregistered
and treatment is changed as described in Cha*ter +
Ne #ulmonary '( #atients ith #ositi&e s#utum smears at the start o"
treatment These *atients should be monitored by s*utum smear microsco*y at the end of the
fifth and si@th months /f results at the fifth or si@th month are *ositi8e) a s*utum
s*ecimen should be obtained for culture and D1T Treatment has failed) the T#
Treatment Card is closed Outcome X treatment failure7 and a ne9 one is o*ened
Ty*e of *atient X treatment after failure7 Treatment should follo9 the
recommendations in Cha*ter + /f a *atient is found to harbour a multidrug-resistant
strain of T# at any *oint of time during thera*y) treatment is also declared a failure
1ee 5igure 4' for a monitoring scheme 9ith s*utum smear microsco*y
Ne #ulmonary '( #atients hose s#utum smear microsco#y as negati&e
or not done/ at the start o" treatment
/t is im*ortant to rechec< a s*utum s*ecimen at the end of the intensi8e *hase in case
of disease *rogression due to non-adherence or drug resistance7 or an error at the
time of initial diagnosis ie a true smear-*ositi8e *atient 9as misdiagnosed as
smear-negati8e7$ Pulmonary T# *atients 9hose s*utum smear microsco*y 9as
negati8e or not done7 before treatment and 9hose s*utum smears are negati8e at $
months need no further s*utum monitoring They should be monitored clinically;
body 9eight is a useful *rogress indicator
' B8en if there is e8entually full susce*tibility) a *ositi8e culture confirms *oor res*onse to treatment)
9hich necessitates in8estigation and inter8ention
$ /f the s*utum is found to be smear-*ositi8e) see >ecommendations $ and + abo8e
6
6
-
8/8/2019 5_Guidelines TB.doc
71/161
$. monIorIn# durIn# rEamEn
$.#.! previousl& treated sputum smearpositive pulmonar& T, patients
receiving firstline antiT, drugs
1*utum smear e@amination is *erformed at the end of the intensi8e *hase of
treatment the +rd month7) at the end of the fifth month and at the end of treatment
the eighth month7 /f the country has already de8elo*ed sufficient laboratory
ca*acity) culture and D1T should be *erformed